目的 研究通心络胶囊联合吲达帕胺治疗高血压合并冠心病的临床疗效。方法 选取2013年3月-2015年3月商洛市中心医院收治的高血压合并冠心病患者100例，随机分为对照组和治疗组，每组各50例。对照组患者口吲达帕胺缓释片，1片/次，1次/d。治疗组患者在对照组治疗基础上口服通心络胶囊，3粒/次，3次/d。两组患者均连续治疗1个月。观察两组的临床疗效，同时比较两组患者治疗前后心电图和血脂变化情况。结果 治疗后，对照组和治疗组的总有效率分别为82.0%、94.0%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者ST段压低、ST段抬高、房性期前收缩和室性期前收缩的患者例数均显著减少，同组治疗前后差异有统计学意义（P<0.05）；治疗组下降程度优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组三酰甘油（TG）、总胆固醇（TC）和低密度脂蛋白（LDL-C）显著降低，高密度脂蛋白（HDL-C）显著升高，同组治疗前后差异有统计学意义（P<0.05）；治疗组这些指标的改善程度优于对照组，两组比较差异有统计学意义（P<0.05）。结论 通心络胶囊联合吲达帕胺治疗高血压合并冠心病具有较好的临床疗效，可以显著降低血脂水平，改善心电图情况，具有一定的临床推广应用价值。

Objective To study the effect of Tongxinluo Capsules combined with indapamide in treatment of hypertension with coronary heart disease. Methods Patients (100 cases) with hypertension with coronary heart disease in Shangluo Central Hospital from March 2013 to March 2014 were randomly divided into control and treatment groups, and each group had 50 cases. The patients in the control group were po administered with Indapamide Sustained-release Tablets, 1 tablet/time, once daily. The patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the changes of the electrocardiogram and blood lipids in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.0% and 94.0%, respectively, and there were differences between two groups (P<0.05). After treatment, patients in two groups with ST segment depression, ST segment elevation, premature atrial contraction, and ventricular premature contraction were significantly reduced, and the difference was statistically significant in the same group (P<0.05). And the descending degree in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, TG, TC, and LDL-C in two groups were significantly decreased, and HDL-C was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, those observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusions Tongxinluo Capsules combined with indapamide has clinical curative effect in treatment of hypertension with coronary heart disease, and can significantly reduce blood lipid levels, also can improve the electrocardiogram, which has a certain clinical application value.